Compare Ishares Msci Brazil ETF (EWZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Ishares Msci Brazil ETF trades at $42.93 (market cap $11.30B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.3× Ishares Msci Brazil ETF's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWZ | VRTX | |
|---|---|---|
Market Cap | $11.30B | $127.55B |
Volume | 44,036,597 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $557.96 |
52-Week Low | $28.79 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
